Special Issue

Radiopharmaceuticals: From Design to Applications

Message from the Guest Editor

Radiopharmaceuticals play a pivotal role in nuclear medicine, where they are widely used as diagnostic and therapeutic agents with their most important applications found in the understanding of neurodegenerative diseases, myocardial imaging, and the diagnosis and treatment of cancer. For the potential impact of nuclear medicine in patient management and personalized medicine to be fully realized, there remains an urgent need to develop new radiopharmaceuticals for molecular targets of disease relevance that are not currently addressed while exhibiting optimal in vivo performance. Nevertheless, the development of the "ideal" radiopharmaceutical is challenging since a plethora of issues need to be addressed such as selectivity and specificity for the molecular target in question, feasible chemistry for clinical applications, and optimal pharmacokinetic characteristics. This Special Issue is dedicated to all efforts towards the development of target-specific radiopharmaceuticals aiming to address unmet clinical needs, as well as novel methodologies for the design and development of more effective radiopharmaceuticals with optimal in vivo performance.

Guest Editor

Dr. Aristeidis Chiotellis

National Center for Scientific Research "Demokritos", Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece

Deadline for manuscript submissions

closed (31 March 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/133289

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

